Virax Biolabs Group Limited announced a strategic collaboration with the University of Manchester and the Northern Care Alliance Foundation Trust, who have a track record in working together to deliver translational immunology research  for respiratory viral infections. This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study. As part of the ImRESP clinical study, the ViraxImmune T-Cell assay will be assessed in respiratory disease patients where the role of memory T-cell driven immunity will be evaluated. Furthermore, within the ImRESP clinical study, the T-cell assay will be assessed in a distinct cohort of patients experiencing Long COVID symptoms. This segment of the study will involve the longitudinal assessment of samples, aiming to discern specific phenotypic T-cell profiles associated with these individuals.

This collaboration underscores Virax Biolabs' commitment to advancing diagnostic capabilities and understanding immune responses, particularly in post-viral syndromes and conditions associated with chronic inflammation. The collaboration with the University of Manchester represents a significant step toward developing innovative solutions for diagnosing and managing post-viral syndromes. ImRESP is an observational study sponsored by the Northern Care Alliance Foundation Trust in the UK and has been designed to evaluate the long term effects of respiratory infections on the immune system in many different contexts including long COVID and progression of chronic lung disease.